The refitted facility now houses 300L fermentation capacity and associated down-stream processing technologies for the production of proteins, plasmid DNA and vaccines.
Richter-Helm said that the revamped plant bridges the gap between its research and development site in Hamburg and its large-scale production facility in Bovenau near Kiel, central Germany.
It added that: “[it] has now all common fermentation scales up to 1500L available for GMP production at three different locations, to serve the customers’ needs for consistent quality from pre-clinical development up to market approval and beyond.”
